BioWorld

June 21, 2004

View Archived Issues

OSI's Prosidion Buying Diabetes Drug, Assets For At Least $35M

OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today) Read More

With Poor Data, Inflazyme To Drop LSAID In Asthma

Read More

FBI: Biotech Industry Not Facing Serious Problem' Of Extremists

Read More

After Reagan's Death, Pressure Mounts For Human ESC Reform

Read More

Guilford Licenses GPI 1485 To New Company Symphony

Read More

Other News To Note

Read More

Clarification

Read More